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Abstract. The diagnostic capacity of three malaria rapid diagnostic tests (RDTs), NOW-Malaria-ICT, OptiMAL-IT,
and Paracheck-Pf, was evaluated against expert microscopy in Colombia. We tested 896 patients, of whom microscopy
confirmed 139 P. falciparum, 279 P. vivax, and 13 mixed P.f/P.v infections and 465 negatives. Paracheck-Pf and NOW-
malaria-ICT were more accurate in detecting P. falciparum (sensitivities 90.8% and 90.1%, respectively) in comparison
with Optimal-IT (83.6%). NOW showed an acceptable Pf detection rate at low densities (< 500/L), but resulted in a
higher proportion of false positives. For P. vivax diagnosis, Optimal-IT had a higher sensitivity than NOW (91.0% and
81.4%, respectively). The choice between the two Pf/Pv detecting RDTs balances P. falciparum and P. vivax detection
rates. Considering some degree of P. falciparum overtreatment and failure to detect all P. vivax cases as more acceptable
than missing some cases of P. falciparum, we recommend careful implementation of NOW-malaria-ICT in areas where
microscopy is lacking. The price is however still a constraint.
INTRODUCTION
In Colombia, malaria represents an important health prob-
lem, affecting mainly populations living in rural areas. Re-
mote areas of the country have now become inaccessible be-
cause of a lack of control and constant threat of violence. The
indigenous communities that live in these areas often travel
several hours or days to reach the nearest health services. In
the Zona Atlantica, the northern coastal area of the country,
Médecins sans Frontières (MSF) provides healthcare to these
groups through rural health-posts and mobile clinics. Diagno-
sis and treatment of malaria is an essential service.
In this area of low transmission, treatment of malaria cases
should ideally be based on biologic diagnosis because of the
nonspecific nature of malaria symptoms,
1 and the fact that
infections with P. falciparum and P. vivax cannot be distin-
guished clinically, although different treatment is required.
Detection of parasites in the blood by microscopy remains the
most common method for the diagnosis of malaria in Colom-
bia, but materials, supply lines, and trained staff are not suf-
ficient in the isolated rural areas where MSF works nor easily
applied in mobile clinics. Accurate malaria rapid diagnostic
tests (RDTs) would greatly improve the quality of diagnosis
and treatment of malaria in these remote settings.
Several rapid diagnostic test kits for malaria exist, which
are fast, easy to perform, and can be carried out by relatively
unskilled staff. The most commonly used tests for P. falci-
parum are based on the immuno-chromatographic detection
of the histidine-rich protein-2 (HRP-2), a protein produced
by asexual stages and young gametocytes of P. falciparum
2 or
of Plasmodium lactate dehydrogenase, pLDH.
3 pLDH can be
either species-specific antigens detecting P. falciparum or P.
vivax or ‘pan-malarial’ pLDH, detecting all four species of
Plasmodium.
4 In addition, there is another antigen, aldolase,
which can detect all species of Plasmodium.
5,6 The rapid tests
we were interested in were (1) the Paracheck-Pf, a P. falci-
parum specific test, based on detection of parasite HRP-2,
which has proven its accuracy and usefulness in many MSF-
projects worldwide, (2) the Optimal-IT, a test that can detect
P. falciparum as well as other Plasmodium species by Pf-
specific PLDH and pan-malarial PLDH, and (3) the NOW
malaria ICT, a test that combines Pf-specific HRP-2 with pan-
malarial aldolase.
Most rapid tests have shown high accuracy in laboratory
and field-based studies, though their sensitivity declines at
low parasitemias (< 300–500/L).
7,8 Test performance may
vary for different geographical populations, levels of disease
prevalence, and presence of different parasite species.
9 It has
been suggested that natural immunity in endemic areas may
reduce the sensitivity, but this has not been proven.
10 To
determine the usefulness of RDTs in the specific situation of
low-endemic, mixed P. falciparum and P. vivax malaria in
southern American Colombia, we compared the diagnostic
capacity of Optimal-IT and NOW Malaria ICT with the ca-
pacity of the MSF-standard, Paracheck test and that of expert
microscopy, the latter considered as our ‘gold standard’. Ad-
ditionally, the ease of use of the various tests was evaluated.
MATERIALS AND METHODS
Study area. The survey was performed in a Malaria Center
in Tierralta, Zona Atlantica, Colombia. Colombia is an area
of hypo-endemic malaria transmission with 2–5% annual
parasite rate in the one third of the population that lives at
risk of the disease, which is due to both P. vivax (54%) and P.
falciparum (46%).
11 Rural/jungle areas below 800 meters are
most affected. It is one of the Latin American countries where
malaria morbidity is rising again, due to climate factors and
drug resistance among other factors.
9 Chloroquine-resistant
P. falciparum exists widely (level 44–97%) and resistance to
sulfadoxine/pyrimethamine (0–27%) and amodiaquine (0–
50%) is also reported.
12,13
Patients. Patients of all ages with suspected malaria were
recruited according to routine criteria of the health workers in
the Malaria Center (i.e., fever or a history of fever and/or
other complaints indicating a possible malaria infection). Per-
sons who came for follow-up visits of an earlier episode of
malaria or within 4 weeks after a (confirmed and treated)
malaria infection were excluded. Patients were asked for their
informed consent and when accepted, they had their blood
sampled for blood slides and 3 RDTs. Patients whose results
* Address correspondence to Ingrid van den Broek, Manson Unit,
MSF-UK, 67-74 Saffron Hill, EC1N 8QX London, UK, E-mail:
Ingrid_vandenbroek@yahoo.com
Am. J. Trop. Med. Hyg., 75(6), 2006, pp. 1209–1215
Copyright © 2006 by The American Society of Tropical Medicine and Hygiene
1209were positive for malaria (for any test) were treated according
to the National Protocol with Amodiaquine + Sulfadoxine-
Pyrimethamine + single dose Primaquine for P. falciparum
and Chloroquine + 14 days Primaquine for P. vivax.
Sample size. The sample size was calculated assuming RDT
sensitivities in the range of 70–90%. A number of 140 positive
patients had to be tested to reach a precision of 5% for a
sensitivity of 90%, or 7% for a sensitivity of 80%, with alpha
error  0.05. For proper assessment of sensitivity of the Pf/Pv
tests, this number was required for both P. falciparum and P.
vivax. Applying similar calculations to the specificity, also 140
negative patients had to be tested. Recruitment was contin-
ued until the required number of P. falciparum patients
(more rare than P. vivax or negative) was reached.
Data and sample collection. A patient form was filled with
basic clinical and demographic information. The rapid test
kits were opened only after the patient had been selected and
interviewed by the medical staff. Capillary blood was col-
lected by finger-prick, sampling a standard volume of blood
for each test according to the manufacturer’s instructions,
with the sampling device provided. Finger-pricking was re-
peated when needed to collect enough blood. Each selected
patient had his/her blood examined by four methods: Opti-
mal-IT, Paracheck-Pf, NOW malaria, and microscopy. The
RDTs were compared by the bacteriologists scoring a list of
issues on ease-of-use and other characteristics.
RAPID DIAGNOSTIC TESTS
1. Paracheck-Pf (Orchid Biomedical Systems, Goa, India),
individually packed test cassettes diagnosing P. falciparum
infections by HRP-2 detection, requiring one drop of
blood (5 L) to be collected with a loop-shaped plastic
sampling tool included with the device; there is one test
line that demonstrates P. falciparum infection when it
turns pink and results are read at 15 minutes.
2. Optimal-IT (Diamed AG, Switzerland), individually
packed dipstick kits, detecting parasite pLDH specific for
P. falciparum in one capture site and pan-pLDH detecting
all four Plasmodium species in a separate capture line.
Blood sampling 8–12 L is done with a plastic capillary
pipette provided. The test device consists of two tubes, in
which the dipstick stands for 10 minutes each, so results are
read after 20 minutes.
3. NOW Malaria ICT (Binax, Portland, USA), a card-type
test with one capture line specific for P. falciparum
through Pf HRP-2 detection and the second line detecting
all Plasmodium species based on aldolase. The blood
sample (15 l), collected with a small glass capillary, is
applied to one side of the card, where it runs up first; the
card is then closed. Wash reagent clears the strip in about
10 minutes until control and/or test lines appear as pink-
colored bands in a reading window.
Rapid diagnostic tests were read by the same bacteriologist
and confirmed by a second independent reader when needed,
all according to the manufacturer’s instructions. The first per-
son performed, read and recorded the results of the three
tests and after that a second opinion was obtained from a
second person reading again the same tests and recording the
results. Each person read the RDT without knowing the re-
sult of the other reader or of the blood film. Results were
compared and discussed to come to a consensus in case of
different readings. At the end of this procedure, results were
recorded on the patient’s individual record form.
Microscopy diagnosis. Two thick smears were taken on one
slide and one thin smear on a separate slide. Thick smears
were submerged in methylene blue for 1 second, washed with
buffer solution and left to dry, thereafter stained horizontally
with Field solution (one drop of solution A and one drop of
solution B per 10 mL) in phosphate buffer B for 10 minutes,
in accordance with nationally standard methods. Thin smears
were fixed with methanol but not stained until necessary for
species determination or better examination of the infection.
Thick smears were evaluated by a well-trained, experienced
microscopist, unaware of RDT results. A thick smear was
considered negative if no parasites were seen in at least 200
fields. For positive smears, the number of parasites was
counted in the number of fields needed to reach 200 white
blood cells (WBCs) or 500 WBCs for low densities. Parasite
density per l was calculated assuming a standard of 8000
WBCs per l of blood as per WHO guidelines.
14 Presence of
gametocytes or schizonts was also recorded. Thin smears
were used for species verification.
Quality control. For internal quality control, a second in-
dependent reading was done by a different microscopist on
about one third of the slides, especially low-density parasit-
emias and mixed infections. Slides with discordances between
the two microscopists or between rapid tests and slide-reading
(in terms of positivity and species determination), and a ran-
dom sample of 20% of other slides, were sent to the Univer-
sity of Antioquia for external cross-checking. Disagreement
results between the two were sent on to a third laboratory, of
the National Health Institute in Bogota. In cases in which
both reference laboratories agreed on one diagnosis different
from ours, results were corrected accordingly.
The RDTs had a guaranteed history of proper storage
(temperature 4–30°C, low humidity) and transport conditions,
and were used within shelf life. Only tests from one batch
were used.
Analysis. The performance of Paracheck-Pf, NOW ICT
Malaria, and Optimal-IT tests was expressed by calculating
the sensitivity, specificity, negative predictive value (NPV),
and positive predictive value (PPV), for P. vivax and P. fal-
ciparum separately, taking microscopy results as the “gold
standard”. To assess the performance of the Optimal-IT test
and NOW Malaria for diagnosis of P. vivax, cases with mixed
infections with P. falciparum were excluded, because the pan-
malaria antigen turns up positive due to P. falciparum infec-
tion. For performance on P. falciparum detection, mixed in-
fections with P. falciparum were included. Slides with game-
tocytes only were regarded as negative for further analyses.
Data were analyzed in SPSS 12.0 (Chicago, IL) and Epi-info
6.04 (CDC, Atlanta, GA). Proportions were compared using
the 
2 test. Agreement (kappa statistic, ) between RDT and
microscopy provided an estimation of the reliability of the
RDT ( > 80% was considered as a measure of very good
reliability).
Ethical considerations. The protocol was reviewed and ap-
proved by the Ethical Board of MSF (a committee of external
experts) and the Ethical Board of the University of Antioquia
and received approval from the National Institutes of Health,
Bogotá. The provincial and local health authorities in Tier-
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study by spreading information to their staff in rural health
centers and the local population. Selected patients or the
caregivers of children under 15 years were asked for their
informed, written consent. The patients in study were taken
care of in exactly the same way as non-study patients, except
for the few for whom an extra finger-prick was needed to
collect enough blood.
RESULTS
From May 10, 2005 to July 11, 2005, a total of 2937 patients
visited the Malaria Center in Tierralta, of which 896 patients
were included in our study. According to the microscopy re-
sults, 139 had P. falciparum infections, 279 P. vivax, 13 mixed
infections of Pf/Pv, and 465 patients were negative for ma-
laria, including two with P. falciparum gametocytes only. The
majority of patients were adults (79%) (Table 1). Most of the
patients were male (646 of 896, 72%), often workers from the
forest-based agricultural locations around Tierralta. The pro-
portion positive for P. falciparum was 17% and for P. vivax
33%. The parasite densities of patients were for the most part
below 5000 parasites per l of blood. The geometric mean
parasite density was similar, about 2300 p/l for both the
falciparum and the vivax infections.
Quality control of 226 slides in the first reference labora-
tory resulted in 16 different slide results; these were re-read in
the second reference laboratory finally leading to 11 results
for which diagnosis differed from the MSF bacteriologists,
hence a ‘disagreement rate’ of 4.9%. Discordances were six
infections classified as mixed P. falciparum/P. vivax, which
were diagnosed as P. vivax by the other laboratories, four
low-density P. falciparum infections (39–240 trophozoites per
l of blood) that were regarded as negative in the two other
laboratories and one mixed infection that the others classified
as P. falciparum only. For further calculations these 11 cases
were adapted to the diagnosis of the reference laboratories.
Rapid diagnostic tests versus microscopy. The results of mi-
croscopy were in agreement in 93% of cases for Optimal-IT,
87% with NOW malaria ICT, and 98% of cases for Paracheck
(P. falciparum only). Diagnosis by Optimal-IT gave 10 false
positives (3 P. falciparum, 6 Pan-Plasmodium,a n d1P f+
Pan-Pl) and 46 false negatives (19 P. falciparum,2 5P. vivax,
and 2 mixed). The NOW resulted in 47 false positives (44 P.
falciparum, 1 pan-Pl, and 2 Pf + Pan-Pl) and 54 false negatives
(4 P. falciparum and 48 P. vivax and 2 mixed). Paracheck gave
1 false P. falciparum and 15 false negatives (9 P. falciparum
and 6 mixed). NOW and Paracheck gave a positive result for
pure P. falciparum when microscopy indicated a pure P. vivax
infection in four and three cases, respectively (Table 2).
Validity of the rapid diagnostic tests. The sensitivity of the
NOW test for P. falciparum was similar to that of Paracheck
(91% and 90% with 95% CI: 85–95 and 84–94), whereas Op-
timal-IT had a somewhat lower sensitivity (84%, 95% CI:
77–89), but this difference was not significant (Table 3). The
specificity for P. falciparum of NOW malaria ICT was signifi-
TABLE 1
Baseline characteristics of study participants, MSF Tierralta, Colombia, 2005
Under 5 years
N (%)
5 to < 15 years
N (%)
15 years and older
N (%)
Total
N (%)
Number of patients 73 (8.1) 120 (13.4) 703 (78.5) 896
Sex: M/F (% F) 29/44 (39.7) 42/78 (35.0) 180/523 (25.6) 251/645 (28.0)
Age* 2.4 ± 1.1 9.5 ± 2.9 28.9 ± 11.7 24.2 ± 13.9
(1–4.5) (5–14) (15–73) (1–73)
Temperature* (°C) 37.0 ± 1.1 37.0 ± 1.1 36.6 ± 0.8 36.7 ± 0.9
(34.2–40.2) (34.9–40.4) (34.2–40.0) (34.2–40.4)
Fever (T > 37.5°C) 20 (27.4) 33 (27.5) 95 (13.5) 148 (16.6)
Fever history in 2 days 68 (93.2) 113 (94.2) 634 (90.2) 815 (91.0)
P. falciparum 5 (6.8) 20 (16.7) 114 (16.2) 139 (15.5)
P. vivax 23 (31.5) 31 (25.8) 225 (32.0) 279 (31.1)
Mixed Pf/Pv 0 2 (1.7) 11 (1.6) 13 (1.5)
Negative 45 (61.6) 67 (55.8) 353 (50.2) 465 (51.9)
Parasite density P.f.† 1862 4654 2200 2438
(per l) (40–25,600) (39–45,898) (39–87,560) 39–87,560)
Parasite density P.v.† 6520 4653 1778 2196
(per l) (40–38,990) (40–35,400) (39–42,912) (39–42,912)
* Values given as mean ± SD (standard deviation) and range (min-max value).
† Parasite density given as geometric mean and range.
TABLE 2
Results of malaria blood tests of study patients by microscopy versus RDT: Optimal-IT, NOW malaria ICT, and Paracheck Pf. MSF Tierralta,
Colombia, 2005
Microscopy N
Optimal-IT NOW malaria ICT Paracheck
Neg Pf Pf + Pan-Pl* Pan-Pl* only Neg Pf Pf + Pan-Pl* Pan-Pl* only Neg Pf
Negative 465 455 3 1 6 418 44 2 1 464 1
P. falciparum 139 19 1 119 0 4 29 106 0 9 130
P. vivax 279 25 0 9 245 48 4 20 207 276 3
Mix Pf/Pv 13 2 0 7 4 2 1 8 2 6 7
Total 896 501 4 136 255 472 78 136 210 755 141
* Pan-Pl  Pan-Plasmodium line positive.
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100]) and Optimal-IT (98% [97–99]). The Pf Positive Predic-
tive Value of NOW was low (66% [(59–73]). For non-P. fal-
ciparum NOW scored lower in sensitivity than Optimal-IT
(81% [76–86]) versus 91% (CI 87–94). The specificity for non-
P. falciparum in both Optimal-IT and NOW test was high
(99% each). Kappa  values showed that for P. falciparum
Paracheck was most reliable, with a  value of 0.92; the NOW
test scored lower (0.71) and Optimal-IT intermediate (0.84).
For non-P. falciparum, the  values of Optimal-IT and NOW
were 0.91 and 0.84, respectively.
Sensitivity at different parasitemia levels. Table 4 shows the
sensitivity of the tests for P. falciparum and non-P. falciparum
infections in different classes of parasite density. For P. fal-
ciparum infections, the NOW test performed better at lower
densities as compared with the Optimal-IT, while the sensi-
tivity of Paracheck was between the two. For non-P. falci-
parum both Optimal-IT and NOW showed a higher detection
limit than for P. falciparum; Optimal-IT was better than
NOW test.
Evaluation of ease-of-use of the rapid tests. Overall, both
Paracheck and NOW malaria ICT tests were evaluated as
very easy to perform, though the sampling methods for blood
collection needed some practice. Optimal-IT was evaluated as
less practical due to difficulties with the sampling pipette,
added to the fact that this test device has a wobbly design
(standing up) and the dipstick needs changing from the first to
the second well, timed halfway through the procedure, which
takes 20 minutes. The NOW test yielded a high number of
lines recorded as doubtful: 72 of 214 P. falciparum lines were
scored ‘weak’ or ‘very weak’ by the reader. Of these, eight
were true Pf-positive of which four had low parasitemias (<
500/L) and 64 were false Pf-positive, which included 20 in-
fections diagnosed as P. vivax by microscopy and one case of
Pf-gametocytes. Also 83 pan-malaria lines were annotated
(very) weak of which 72 were true Plasmodium-positive of
which 4 with low Pf and 11 with low Pv parasitemias. Like-
wise, some of the test lines for Optimal-IT were (very) weak:
(i) 28 P. falciparum lines with 21 true Pf-positive cases of
which eight had low parasitemias and seven false Pf-positives,
which included six P. vivax infections and (ii) 28 pan-malaria
lines with 22 true Plasmodium-positives of which 4 with low
Pf and 12 with low Pv parasitemia. The weak lines were not
seen with Paracheck tests, but these had occasionally a prob-
lem with dry white patches (partly) preventing the control or
test line to become visible.
DISCUSSION
Rapid diagnostic test capacities. Here we have presented
the results of a study on the diagnostic capacity of three rapid
diagnostic tests for malaria in an area of low malaria trans-
mission of P. falciparum and P. vivax, in South America. Our
data show that the rapid diagnostic tests are potentially useful
tools in the diagnosis of malaria in this setting. The levels of
TABLE 3
Diagnostic performance of rapid tests to detect malaria parasites: A) for P. falciparum and B) for P. vivax. MSF Tierralta, Colombia, 2005
Optimal-IT NOW ICT Paracheck 2
P. falciparum (n  896) (n  896) (n  895) P values
Sensitivity (95% CI) 83.6 (76.5–88.9) 90.8 (84.7–94.7) 90.1 (84.0–94.2) 0.097
Specificity (95% CI) 98.3 (96.9–99.0) 90.6 (88.2–92.5) 99.5 (98.5–99.8) < 0.001
PPV (95% CI) 90.7 (84.3–94.8) 66.3 (59.4–72.7) 97.2 (95.0–99.1) < 0.001
NPV (95% CI) 96.7 (95.1–97.8) 98.0 (96.5–98.8) 98.0 (96.7–98.8) 0.18
 (95% CI) 0.84 (0.78–0.90) 0.71 (0.65–0.77) 0.92 (0.86–0.98)
Non-P. falciparum*( n  883) (n  883)
Sensitivity (95% CI) 91.0 (86.9–94.0) 81.4 (76.2–85.7) 0.001
Specificity (95% CI) 98.6 (97.0–99.4) 99.4 (98.2–99.9) 0.189
PPV (95% CI) 97.3 (94.4–98.9) 98.7 (96.2–99.7) 0.28
NPV (95% CI) 95.0 (92.8–96.8) 90.5 (87.6–92.8) 0.003
 (95% CI) 0.91 (0.83–0.99) 0.84 (0.76–0.92)
* Mixed infections were excluded from calculations for non-P. falciparum.
TABLE 4
Sensitivity to detect (A) P. falciparum and (B) P. vivax at different parasite densities. MSF Tierralta, Colombia, 2005
P. falciparum Optimal-IT NOW ICT Paracheck Microscopy 2
Parasite density N % detected P values
< 100 par/l 16 25.5% 68.8% 50.0% 15 Pf, 1 Pf+Pv 0.002
100–500 par/l 14 42.9% 92.8% 78.6% 13 Pf, 1 Pf+Pv 0.01
500–5000 par/l 53 90.6% 96.3% 92.5% 48 Pf, 5 Pf+Pv 0.5
> 5000 par/l 69 100.0% 100.0% 100.0% 64 Pf, 5 Pf+Pv –
P. vivax
< 100 par/l 19 15.8% 0.0% 19 Pv 0.2
100–500 par/l 46 80.4% 32.6% 41 Pv < 0.001
500–5000 par/l 91 100.0% 97.8% 91 Pv 0.2
> 5000 par/l 123 100.0% 100.0% 123 Pv –
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81–91% for P. vivax.
For P. falciparum detection the HRP2 test, the NOW ma-
laria ICT, as well as Paracheck-Pf, appeared to be more sen-
sitive than the pLDH test, Optimal-IT. The NOW test had a
better capacity to detect lower density P. falciparum infec-
tions, but it gave a relatively high number of false-positive
results (11% of all positives), so that its specificity and PPV
were lower than that of the other two tests. For non-P. falci-
parum infections, here P. vivax, Optimal-IT (pLDH) was
more sensitive than NOW malaria ICT (aldolase). Both Op-
timal-IT and NOW ICT revealed a relatively large number of
P. vivax false negatives, missing respectively 9% and 17% of
the infections. At lower P. vivax densities the tests performed
less accurately than for P. falciparum. Doubtful, weakly col-
ored test lines, found in positive as well as negative cases,
were a problem encountered with NOW and Optimal-IT.
Some of these, but not all, had low parasitemias.
The limitation of the study in this setting is the potential
overestimation of the accuracy of microscopy. Hypothetically,
the RDTs might be more sensitive than microscopy. If so, at
least part of the 41 cases in which the NOW test indicated a
P. falciparum infection as opposed to microscopy and the
results of the other two RDTs, and the six cases in which
Optimal-IT diagnosed P. vivax but microscopy, Paracheck,
and NOW were all negative, might have been false-negative
microscopy results rather than false-positive RDT results.
Vice versa, some false-negative RDT results may have been
false-positive microscopy results [e.g., slides read as very low
density P. falciparum (N  4), P. vivax (N  23), or mixed
infections (N  2)] for which all three RDTs gave a negative
result. Also, the few cases where microscopy detected P.
vivax only and the RDTs indicated P. falicparum also (N  5)
may have been microscopy errors. We have applied maxi-
mum efforts to achieve expert reading in field conditions, with
rigorous quality control procedures in place, such as double
reading of difficult slides in our laboratory and blinded re-
reading of a considerable number of slides in two reference
laboratories. Expert microscopy is judged by Moody to detect
parasite densities down to 50 par/l
6 and remains the current
universal ‘gold standard,’ which is widely available.
7,8 How-
ever, taking a blood sample on filter paper to confirm para-
sitemia by means of polymerase chain reaction can be con-
sidered for future studies.
Our results are in line with findings from other studies in
areas of low to medium endemicity for malaria. Optimal was
evaluated positively by most researchers but not all: in Latin
America, sensitivities for P. falciparum averaged 82% (range
42–100%) and for P. vivax 88% (65–100), including studies
from Colombia,
15–17 Honduras,
4,18 Mexico,
19 Peru,
20 and
Brazil;
21 in Asia it showed about 87% (79–94) sensitivity for
P. falciparum and 80% (65–95) for P. vivax (Afghanistan,
22
Thailand,
23 Pakistan,
24 Kuwait
8). The NOW test and its pre-
decessor ICT Pf/Pv were reported to be very sensitive for P.
falciparum, about 96% (range 89–100) and a bit lower but
acceptably sensitive for non-P. falciparum infections, about
87% (range 75–100, Colombia [Mendoza and others, unpub-
lished data], Indonesia,
5 Thailand
25,26). Paracheck Pf gener-
ally showed good diagnostic capacity, 96% (range 92–100) in
Thailand,
27 Vietnam,
28 and India.
29
High-endemic versus low-endemic areas. Reports on the
same rapid tests from high-endemic malaria areas are scarce,
but they generally show a higher sensitivity: the older version
of the NOW-test, ICT Pf/Pv 100% and Optimal 94% (Tan-
zania
30), and Paracheck 97% (Uganda
31). The hypothesis of
Fryauff and others
8—that natural immunity against malaria
might reduce the sensitivity of RDTs—is not confirmed by
this rough comparison. The main factor explaining the differ-
ence in sensitivity between high-endemic and low-endemic
areas seems to be the parasite density. In our study group of
symptomatic malaria patients, geometric mean parasite den-
sity was about 2300/L for both species, whereas worldwide it
is said to be 20,000 for P. vivax and 20,000 to 500,000 for P.
falciparum.
32 A total of 40% of P. falciparum infections and
38% of P. vivax infections had a parasite density below 2000
par/l, and nearly 20% and 25% were below 500 par/l. This
proportion is higher than in high-endemic areas such as in
Africa: in studies in DRC and Sudan (data from
33–35)w es a w
that only 8–11% of P. falciparum infections of clinically ill
children under 5 years were below 2000 par/l. Hence, in
areas of low and moderate malaria transmission, such as
South America and Asia, rapid tests require a high sensitivity
at lower densities of infection, to serve the non-immune popu-
lations that can suffer from clinical disease at much lower
infection grades, as opposed to people in high-endemic areas
in sub-Saharan Africa.
The PPV and NPV depend on the proportion of positive
patients seen. The PPV reduces with lower prevalence,
whereas the NPV increases.
36 In the group of patients se-
lected for study, 17% had a P. falciparum infection; however,
of all patients visiting the Malaria Center in the period of
study, only 10% were P. falciparum positive. This is higher
than the annual parasite rates reported for Colombia.
10
Health posts and mobile clinics where the RDT will be ap-
plied will probably see a lower positivity rate than in this
specific Malaria Center where patients come for malaria di-
agnosis and treatment specifically. Thus, the PPV for P. fal-
ciparum of the NOW malaria ICT can be even lower than the
66% we reported here, related to a proportional increase in
false positives among the few testing positive.
Implementation of rapid diagnostic tests. In Colombia, the
tests that detect all Plasmodium species have an obvious
added value above those detecting P. falciparum only. A test
with HRP-2 for P. falciparum and pLDH for P. vivax detec-
tion would have given the best combined results, with both
sensitivities over 90%; however, the tests available now com-
bine HRP2–aldolase (NOW ICT) and Pf pLDH-pan pLDH
(Optimal-IT). The NOW test appears to be more sensitive for
P. falciparum. It will however lead to more false- positive
results. But if we accept some degree of overtreatment and
prioritize P. falciparum over P. vivax, then NOW is the test of
choice. The NOW test was considered easier to perform than
the Optimal-IT, and as a card test is also very easy to read.
The scoring of weak positive lines should be addressed in
training.
In areas in Colombia where microscopy is in use and qual-
ity requirements of trained staff and proper equipment can be
met, this is still the more accurate way to diagnose malaria in
this zone of mixed Pf/Pv prevalence. The RDTs are quicker,
but still far from perfect in the diagnosis of different Plasmo-
dium species or mixed infections.
The disadvantage of the Pf/Pv combination rapid tests is
that their price (US $2.5) is about 5 times more than the price
of the ‘Pf-only’ test (US $0.5), whereas microscopy is esti-
EVALUATION OF THREE MALARIA RAPID TESTS IN COLOMBIA 1213mated to cost 0.12 to 0.40 US$ in endemic countries. The
Colombian health system is privatized and health centers and
hospitals often operate on a cost-recovery scheme; therefore
a large proportion of the costs must be paid for by the patients
themselves. RDTs should not replace microscopy in Colom-
bia in areas where there is a good network of skilled techni-
cians and where microscopy remains the best option. Never-
theless, RDTs will be a useful tool in remote, deprived set-
tings.
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